Literature DB >> 11132037

Lithotripsy in the treatment of urinary lithiasis.

P Tombolini1, M Ruoppolo, C Bellorofonte, C Zaatar, M Follini.   

Abstract

Based on an extensive review of the literature and on our own clinical experience, this article attempts to present clear guidelines for the management of various kidney stones, particularly regarding the extracorporeal shock waves lithotripsy (ESWL) treatment nowadays. Few technical developments have changed medicine more within a short period of time than ESWL. Fifteen years after the first clinical application, ESWL has gained world-wide acceptance as first choice therapy for most forms of urolithiasis. Ninety-eight per cent of stones can be successfully fragmented by the application of shock-waves, but the ability of the kidney and ureter to clear the resulting fragments is far more important in terms of successful treatment outcome. Increasing experience with new ultrasound-guided lithotriptors has shown that there are some advantages: cost reduction, permanent monitoring and lack of exposure to ionising radiations. ESWL is a safe procedure for the treatment of urolithiasis; nevertheless some problems remain. In ureteric stones, ureteroscopy (rigid or flexible device) allows a rate of stone-free patients better than ESWL. For treatment of large staghorn calculi combined approach of PCNL and ESWL is preferred. For stones located at lower calyx, the stone-free rate in patients treated by ESWL fell to 50%, when unfavourable anatomy is present. The potential long-term renal damage, associated with ESWL in children, have delayed the acceptance of shock-waves into paediatric practice. Recent reports suggest that the renal damage, including the potential risk of hypertension induced by ESWL, is mild and transient. A subgroup of patients (e.g. solitary kidney, impaired renal function, children) required further attention. The fate of residual fragments is unclear. In some cases residual lithiasis tend to result in regrowth and further progression, although ESWL itself does not increase the recurrence rate of urolithiasis. Nevertheless follow-up of stone patients after ESWL is mandatory and the ultimate goal of treating stones by whatever means is to get the patient stone-free and prevent recurrence.

Entities:  

Mesh:

Year:  2000        PMID: 11132037

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  6 in total

1.  Immediate or delayed SWL in ureteric stones: a prospective and randomized study.

Authors:  Sami Uguz; Temucin Senkul; Hasan Soydan; Ferhat Ates; Ilker Akyol; Ercan Malkoc; Kadir Vehbi Baykal
Journal:  Urol Res       Date:  2012-07-05

2.  The topical application of tranexamic acid to control bleeding in inguinal hernia surgery candidate patients: A randomized controlled trial.

Authors:  Seyed Muhammad Mehdi Ghaffari Hamedani; Ali Akbari; Sohrab Sayaydi; Zakaria Zakariaei; Mahmood Moosazadeh; Javad Boskabadi; Mahshid Naserifar; Saeed Kargar Soliemanabad
Journal:  Ann Med Surg (Lond)       Date:  2021-08-10

Review 3.  Herbal medicines in the management of urolithiasis: alternative or complementary?

Authors:  Veronika Butterweck; Saeed R Khan
Journal:  Planta Med       Date:  2009-05-14       Impact factor: 3.352

4.  Studying inhibition of calcium oxalate stone formation: an in vitro approach for screening hydrogen sulfide and its metabolites.

Authors:  S Vaitheeswari; R Sriram; P Brindha; Gino A Kurian
Journal:  Int Braz J Urol       Date:  2015 May-Jun       Impact factor: 1.541

5.  Bryophyllum pinnatum Leaf Extracts Prevent Formation of Renal Calculi in Lithiatic Rats.

Authors:  Mahendra Yadav; Vijay D Gulkari; Manish M Wanjari
Journal:  Anc Sci Life       Date:  2016 Oct-Dec

6.  Nephroprotective effect of Bryophyllum pinnatum-mediated silver nanoparticles in ethylene glycol-induced urolithiasis in rat.

Authors:  Revati Dighade; Ranjit Ingole; Pramod Ingle; Aniket Gade; Sunil Hajare; Maheshkumar Ingawale
Journal:  IET Nanobiotechnol       Date:  2021-03-10       Impact factor: 2.050

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.